|Articles|July 1, 2001

July 2001
Volume 7
Issue 7

Economic Evaluation of Lamivudine Compared with Interferon-Alpha in the Treatment of Chronic Hepatitis B in the United States

Author(s)Elizabeth A. Brooks, PhD, Larry F. Lacey, PhD, Sarah L. Payne, MBA

Download PDF: Economic Evaluation of Lamivudine Compared with Interferon-Alpha in the Treatment of Chronic Hepatitis B in the United States

Articles in this issue

about 25 years ago

Article

Electronic Prescribing in Ambulatory Practice: Promises, Pitfalls, and Potential Solutions

about 25 years ago

Article

Another Theory About Healthcare Expenditures and Inflation Refuted by the Facts

about 25 years ago

Article

Decomposing Pharmaceutical Cost Growth in Different Types of Health Plans

about 25 years ago

Article

Promoting Smoking Abstinence in Pregnant and Postpartum Patients: A Comparison of Two Approaches

about 25 years ago

Article

Primary Care Physician Job Satisfaction and Turnover

about 25 years ago

Article

Physician Characteristics and the Initiation of Beta-Adrenergic Blocking Agent Therapy After Acute Myocardial Infarction in a Managed Care Population

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Economic Evaluation of Lamivudine Compared with Interferon-Alpha in the Treatment of Chronic Hepatitis B in the United States

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol

FTC Reaches Settlement With CVS Caremark to Curb Insulin Rebate Practices, Cut Patient Costs

Remote Monitoring Captured Between-Visit Symptom Swings in Myasthenia Gravis

SNAP Participation Linked to Smaller Colorectal Screening Gap

Innovation Is Outpacing Reimbursement, Health System Execs Warn